Pharmacogenetic influences on treatment response and toxicity in colorectal cancer

摘要: Current use of chemotherapeutic and targeted agents for advanced colorectal cancer (CRC) results in high tumor response rates relatively long overall patient survival. Fluoropyrimidines, irinotecan, oxaliplatin are highly active first-line salvage therapy cancer. Targeted therapies, including anti-angiogenesis anti-epidermal growth factor receptor antibodies, have been incorporated with traditional chemotherapy offer additional options patients CRC. However, there is marked variability to therapy, as well frequency severity toxicities. Molecular markers pharmacogenomic profiling may improve prediction who will experience significant benefit or toxicity from currently available agents. Validation these predictive factors prospective clinical trials now necessary allow a rational systematic individualization therapy.